REV-ERB agonist comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-04-20. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule ligand; not a hormone or peptide |
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| CAS Registry Number | 1379686-30-2 | Unique chemical identifier |
| Common synonyms | SR9009; stenabolic | Stenabolic is informal and not an official name |
| Reported targets | REV-ERBα and REV-ERBβ | Nuclear receptors linked to circadian and metabolic regulation |
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
=== Political views === Psychologists in the happiness community feel politics should promote population happiness. Politics should also consider level of human happiness among future generations, concern itself with life expectancy, and focus on the reduction of suffering. Based on political affiliation, some studies argue conservatives, on average, are happier than liberals. A potential explanation is greater acceptance of income inequalities in society leads to a less worried nature. Luke Galen, Associate Professor of Psychology at Grand Valley State University, mentioned political commitments as important because they are a sort of secular world view that, like religion, can be generally beneficial to coping with death anxiety (see also Terror management theory and religion and happiness).
=== Forestry === In commercial forestry, the transplanting of crop trees to new locations often requires an accompanying ectomycorrhizal partner. This is especially true of trees that have a high degree of specificity for their mycobiont, or trees that are being planted far from their native habitat among novel fungal species. This has been repeatedly shown in plantations involving obligate ectomycorrhizal trees, such as Eucalyptus and Pinus species. Mass planting of these species often requires an inoculum of native EcM fungi for the trees to prosper. Sometimes ectomycorrhizal plantation species, such as pine and eucalyptus, are planted and promoted for their ability to act as a sink for atmospheric carbon. However, the ectomycorrhizal fungi of these species also tend to deplete soil carbon, making this use of plantations controversial.
== External links == Clinical trial number NCT04710576 for "A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD) (AGAVE-201)" at ClinicalTrials.gov
BMPs for clinical use are produced using recombinant DNA technology (recombinant human BMPs; rhBMPs). Recombinant BMP-2 and BMP-7 are currently approved for human use. rhBMPs are used in oral surgeries. BMP-7 has also recently found use in the treatment of chronic kidney disease (CKD). BMP-7 has been shown in murine animal models to reverse the loss of glomeruli due to sclerosis. A 2022 study by researchers from the Mayo Clinic, Maastricht University, and Ethris GmBH, a biotech company that focuses on RNA therapeutics, found that chemically modified mRNA encoding BMP-2 promoted dosage-dependent healing of femoral osteotomies in male rats. The mRNA molecules were complexed within nonviral lipid particles, loaded onto sponges, and surgically implanted into the bone defects. They remained localized around the site of application. Compared to receiving rhBMP-2 directly, bony tissues regenerated after mRNA treatment displayed superior strength and less formation of massive callus.
Sources: en.wikipedia.org
Professor Reddi discovered that bone induction is a sequential multistep cascade involving chemotaxis, mitosis, and differentiation. Early studies in his laboratory at the University of Chicago and National Institutes of Health unraveled the sequence of events involved in bone matrix-induce bone morphogenesis. Using a battery of in vitro and in vivo bioassays for bone formation, a systematic study was undertaken in his laboratory to isolate and purify putative bone morphogenetic proteins. Reddi and colleagues were the first to identify BMPs as pleiotropic regulators, acting in a concentration dependent manner. They demonstrated first that BMPs bind the extracellular matrix, are present at the apical ectodermal ridge in the developing limb bud, are chemotactic for human monocytes, and have neurotropic potential. His laboratory pioneered the use of BMPs in regenerative orthopedics and dentistry. Professor Reddi's h-index is 109 with over 300 peer-reviewed manuscripts.
Microbial toxins are toxins produced by micro-organisms, including bacteria, fungi, protozoa, dinoflagellates, and viruses. Many microbial toxins promote infection and disease by directly damaging host tissues and by disabling the immune system. Endotoxins most commonly refer to the lipopolysaccharide (LPS) or lipooligosaccharide (LOS) that are in the outer plasma membrane of Gram-negative bacteria. The botulinum toxin, which is primarily produced by Clostridium botulinum and less frequently by other Clostridium species, is the most toxic substance known in the world. However, microbial toxins also have important uses in medical science and research. Currently, new methods of detecting bacterial toxins are being developed to better isolate and understand these toxins. Potential applications of toxin research include combating microbial virulence, the development of novel anticancer drugs and other medicines, and the use of toxins as tools in neurobiology and cellular biology.
The Chinese Room (formerly Thechineseroom) is a British video game developer based in Brighton that is best known for exploration games. The company originated as a mod team for Half-Life 2, based at the University of Portsmouth in 2007, and is named after John Searle's Chinese room thought experiment. It was a subsidiary of Sumo Digital from 2018 to 2025.
After receiving a missile targeting device disguised as a gem from Agent Abrella, she travels to Earth in the Kaijuki Devil Capture 5 (デビルキャプチャー5, Debiru Kyapuchā Faibu), which is destroyed by Deka Bike Robo while she is captured by S.P.D.'s Earth unit. She escapes to rekindle a former relationship, but is confronted by the Dekarangers and learns of Abrella's true intentions. Once the Dekarangers stop the missile and jettison Faraway to safety, she is pardoned. Faraway is portrayed by Aja (あじゃ). Tokasaian Princess Io Yonmerluicchi (トカーサ星人イオ・ヨンマールイッチ, Tokāsa Seijin Io Yonmāruitchi): A princess from Planet Tokasa who resembles Umeko. Io Yonmerluicchi is portrayed by Mika Kikuchi, who also portrays Umeko. Chanbenarian Gin (チャンベーナ星人ギン, Chanbēna Seijin Gin): A feline alien child from Planet Chanbenar who tries to steal medicine from Hakutaku, for his sick mother, after he was unable to buy it with a pearl he found, but is stopped and befriended by Sen-chan. After surviving an attempt on his life by an Alienizer named Gineka, who used the pearl in his Kaijuki game, Gin's mother receives medicine from Hakutaku at Sen-chan's request. Gin is voiced by Yōko Teppōzuka (鉄炮塚 葉子, Teppōzuka Yōko). Teranian Chou San (テラン星人チョウ・サン, Teran Seijin Chō San): A retired veteran detective from Planet Teran who seeks revenge on an Alienizer named Raja Namunan for killing his daughter 13 years prior, but was never able to prove it. In the present, Jasmine shows him the errors of his ways while confirming his theory. Chou San is voiced by Seizō Katō (加藤 精三, Katō Seizō).
The demand increase is attributed to millennial consumers, and some companies have introduced vegetarian friendly options or done away with isinglass use. A beer-fining agent that is suitable for vegetarians is Irish moss, a type of red algae containing the polymer chemical carrageenan. However, carrageenan-based products (used in both the boiling process and after fermentation) primarily reduce hazes caused by proteins, but isinglass is used at the end of the brewing process, after fermentation, to remove yeast. Since the two fining agents act differently (on different haze-forming particles), they are not interchangeable, and some beers use both. Isinglass finings are also used in the production of kosher wines, although for reasons of kashrut, they are not derived from the beluga sturgeon, because this fish is not kosher. Whether the use of a nonkosher isinglass renders a beverage nonkosher is a matter of debate in Jewish law. Rabbi Yehezkel Landau, in Noda B'Yehuda, first edition, Yore Deah 26, for example, permits such beverages. This is the position followed by many kashrut-observant Jews today. The similar-sounding names has resulted in confusion between isinglass and waterglass (sodium silicate), especially as both have been used to preserve eggs. A solution of isinglass was applied to eggs and allowed to dry, sealing their pores. Eggs were submerged in solutions of waterglass, and a gel of silicic acid formed, also sealing the pores of the eggshell.
Sources: en.wikipedia.org
Symptoms of episcleritis typically include painless redness of the eye (mild pain is possible but atypical), and watery eyes. The pain of episcleritis is typically mild, less severe than in scleritis, and may be tender to palpation. There are two types of episcleritis: the diffuse type, where the redness involves the entire episclera, and the nodular type, where the redness appears more nodular, involving only a small, well-circumscribed area (sectoral). The diffuse type of episcleritis may be less painful than the nodular type. Sometimes, small nodules are present within the episclera, which move slightly over the sclera with gentle pressure. Discharge is absent with episcleritis, and vision is unaffected. Patients with episcleritis experience far less photophobia than patients with uveitis. Episcleritis does not cause the presence of cells or flare in the anterior chamber of the eye. In 80 percent of cases, episcleritis affects only one eye, whereas scleritis often affects both eyes.
In medicine, myopathy is a disease of the muscle in which the muscle fibers do not function properly. Myopathy means muscle disease (Greek : myo- muscle + patheia -pathy : suffering). This meaning implies that the primary defect is within the muscle, as opposed to the nerves ("neuropathies" or "neurogenic" disorders) or elsewhere (e.g., the brain). This muscular defect typically results in myalgia (muscle pain), muscle weakness (reduced muscle force), or premature muscle fatigue (initially normal, but declining muscle force). Muscle cramps, stiffness, spasm, and contracture can also be associated with myopathy. Myopathy experienced over a long period (chronic) may result in the muscle becoming an abnormal size, such as muscle atrophy (abnormally small) or a pseudoathletic appearance (abnormally large). Capture myopathy can occur in wild or captive animals, such as deer and kangaroos, and leads to morbidity and mortality. It usually occurs as a result of stress and physical exertion during capture and restraint. Muscular disease can be classified as neuromuscular or musculoskeletal in nature. Different myopathies may be inherited, infectious, non-communicable, or idiopathic (cause unknown). The disease may be isolated to affecting only muscle (pure myopathy), or may be part of a systemic disease as is typical in mitochondrial myopathies.
=== Plastics === BASF's plastic products include high-performance materials in thermoplastics, foams, and urethanes. Engineering PlasticsBASF's Engineering Plastics consists of the "4 Ultras" – Ultramid polyamide (PA) nylon-based resins, Ultradur, polybutylene terephthalate (PBT), Ultraform, polyacetal (POM), and Ultrason, polysulfone (PSU) and polyethersulfone (PES). StyrenicsBASF Styrenics consists of the Foams and Copolymers. BASF's styrenic copolymers have applications in electronics, building and construction, and automotive components. In 2011 BASF and Ineos blended their global business activities in the fields of styrene monomers (SM), polystyrene (PS), acrylonitrile butadiene styrene (ABS), styrene butadiene copolymers (SBC) and other styrene-based copolymers (SAN, AMSAN, ASA, MABS) into a joint venture named Styrolution. PolyurethanesBASF's Polyurethanes business consists of diverse technologies and finished products. Urethane chemicals are raw materials used in rigid and flexible foams commonly used for insulation in the construction and appliance industries, furniture, packaging, and transportation. FoamsFoams like Styropor are generally used as insulating materials. They are eco-efficient and offer advantages over other materials in terms of cost-effectiveness, preservation of resources and environmental protection. Investments made for insulating materials usually pay for themselves within a short time and contribute to retaining and even enhancing the value of buildings. Polyamides and IntermediatesBASF manufactures polyamide precursors and polyamide.
Other means of fortifying foods via genetic engineering have been explored. Research on rice began in 1982. The first field trials of golden rice cultivars were conducted in 2004. The result was "Golden Rice", a variety of Oryza sativa rice produced through genetic engineering to biosynthesize β-carotene, a precursor of retinol, in the edible parts of rice. In May 2018, regulatory agencies in the United States, Canada, Australia and New Zealand had concluded that Golden Rice met food safety standards. In July 2021, the Philippines became the first country to officially issue the biosafety permit for commercially propagating Golden Rice. However, in April 2023, the Supreme Court of the Philippines issued a Writ of Kalikasan ordering the Department of Agriculture to stop the commercial distribution of genetically modified rice in the country.
The main Imperial Russian Army was commanded by Field Marshal Michael Andreas Barclay de Tolly, who recognized that Napoleon's immediate goal was a decisive battle to crush the main Russian force in the west. In response, the Russian army used scorched-earth tactics as it withdrew east, and harried the Grande Armée with light Cossack cavalry. The Grande Armée did not adjust its operational methods in response. Provisioning such an enormous army with adequate food and fresh water had proven difficult since the very start of the campaign, exacerbated by the sparse terrain of western Russia; diseases such as typhus and dysentery rapidly became rampant among the rank and file. These factors led to most of the losses of the main column of the Grande Armée, which in one case amounted to 95,000 men, including deserters, in a week. The main Russian army retreated for almost three months. This constant retreat led to the increasing unpopularity of Barclay de Tolly (who was a Baltic German and already mistrusted by the Russian elite) and a respected Russian veteran, Prince Mikhail Kutuzov, was made the new Commander-in-Chief by Tsar Alexander. Finally, the two armies engaged in the Battle of Borodino on 7 September, in the vicinity of Moscow. The battle was the largest and bloodiest single-day action of the Napoleonic Wars, involving more than 250,000 men and resulting in at least 70,000 casualties. The battle was indecisive; the French captured the main positions on the battlefield but failed to destroy the Russian army.
Sources: en.wikipedia.org
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.
No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.
Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.